BioVaxys Technology (XCNQ:BIOV) Debt-to-Asset : 0.03 (As of Jul. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Debt-to-Asset?

BioVaxys Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$0.08 Mil. BioVaxys Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$0.00 Mil. BioVaxys Technology's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jul. 2024 was C$2.41 Mil. BioVaxys Technology's debt to asset for the quarter that ended in Jul. 2024 was 0.03.

BioVaxys Technology Debt-to-Asset Historical Data

The historical data trend for BioVaxys Technology's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Debt-to-Asset Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Asset

Get a 7-Day Free Trial

BioVaxys Technology Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	0.07	0.04	0.03

Competitive Comparison of BioVaxys Technology's Debt-to-Asset

For the Biotechnology subindustry, BioVaxys Technology's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Debt-to-Asset falls into.

BioVaxys Technology Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioVaxys Technology's Debt-to-Asset for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0.113
	=	0.00

BioVaxys Technology's Debt-to-Asset for the quarter that ended in Jul. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.081	+	0)	/	2.408
	=	0.03

BioVaxys Technology (XCNQ:BIOV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BioVaxys Technology Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BVAXF:USA 5LB:Germany

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Executives

James Passin	Director, Senior Officer
Kenneth Kovan	Senior Officer

BioVaxys Technology Headlines

No Headlines